Third-Line’s A Charm: Amgen Aims To Take A BiTE Out Of Pretreated SCLC

 
• By Alaric DeArment
Amgen presented data at WCLC for its bispecific antibody, tarlatamab, in small-cell lung cancer • Source: Shutterstock

More from Anticancer

More from Therapeutic Category